Channel BannerChannel Banner
XYv30g7TKVMXYv30g7TKVM

Ivermectin prophylactic study from India

804,036
Socialcounts.OrgEnter Fullscreen (f)
21,535
likes
6,848
comments
daily view 0
monthly view 0

Share

Live Analytics

Comments 0

Ivermectin prophylactic study from India Analytics Table

Income Estimates for Ivermectin prophylactic study from India

Based on this YouTube video's total view count of 804K views and industry-standard rates, the estimated total earning is $563 - $1.60K through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

About Ivermectin prophylactic study from India

Explore Ivermectin prophylactic study from India with 804,036 views, 21,535 likes, and 6,848 comments. Experience the impact of this video content that has captured audience attention.

Ivermectin in India, Prophylactic role of ivermectin in SARS-CoV-2 infection among healthcare workers https://www.aiims.edu/en.html https://assets.researchsquare.com/files/rs-208785/v1/d6ff79a3-d354-4aba-a6b0-4bc123bbd225.pdf https://www.researchsquare.com/article/rs-208785/v1 Background Healthcare workers (HCWs) are vulnerable to getting infected withSARS-CoV-2 Preventing HCWs from getting infected is a priority to maintain healthcare services The therapeutic and preventive role of ivermectin in COVID-19 is being investigated Based on promising results of in vitro studies of oral ivermectin, this study to look at prophylactic role of oral ivermectin Methods Prospective cohort study was conducted at AIIMS Bhubaneswar Two-doses of oral ivermectin, 300 μg/kg at a gap of 72 hours Primary outcome, COVID-19 infection in the month following Of 3892 employees, 3532 (90.8%) participated in the study Ivermectin uptake n = 2, 384 (67.5%) Non uptake, n = 1147 (32.5%) Results Development of symptomatic infection 331 participants, developed symptoms 131 in takers 200 from non takers Ivermectin takers, 6% Non takers, 15% Testing positive, 201 Ivermectin takers, 2% Non takers, 11.7% Implications for transmission HCWs who had taken two-doses (Single dose did not reach significance) Significantly lower risk of contracting COVID-19 disease during the following month was 0.18 Adjusted Relative Risk 0.17 1.8% reported adverse events, mild and self-limiting Conclusion and relevance Two-doses of oral ivermectin (300 μg/kg given 72 hours apart) as chemoprophylaxis among HCWs reduces the risk of COVID-19 infection by 83% in the following month. Safe, effective, and low-cost chemoprophylaxis have relevance in the containment of pandemic alongside vaccine. https://www.pharmaceutical-technology.com/news/aiims-study-covid-19/ AIIMS Director, Gitanjali Batmanabane Earlier, at least 20 to 25 HCWs were getting infected with the virus daily. After the workers started taking ivermectin, the number of infection has come down to one or two per day Critique The safety of the drug has been established by its large-scale use in the last four decades for various indications such as onchocerciasis, scabies, head lice, and other parasitic infestations https://www.facebook.com/john.l.campbell1/ https://healthfeedback.org/claimreview/ivermectin-isnt-a-highly-effective-drug-for-treating-covid-19-tess-lawrie/?fbclid=IwAR2ahWjmOXuMx2u6FKgF9wTCESwHtN9EXKiKsTWCOoAygBb_P5thfAyOilA

About YouTube Real-Time View Count

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.

Embed Widget

Parameters:

  • fullscreen=true - Fullscreen counter
  • graph=true - Live graph chart
  • counter=0/1/2 - Select counter (0=likes, 1=views, 2=comments)
URL

Click to copy the embed URL to your clipboard